nach oben

Erschienen in:

01.11.2014 | Research Article

Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in Punjabi population from North West India

verfasst von: Ruhi Kapahi, Kamlesh Guleria, Vasudha Sambyal, Mridu Manjari, Meena Sudan, Manjit Singh Uppal, Neeti Rajan Singh

Erschienen in: Tumor Biology | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to evaluate the association of seven VEGF promoter polymorphisms with breast cancer risk in Punjabi population from North West India. We screened DNA samples of 102 sporadic breast cancer patients and 102 unrelated healthy, gender, and age-matched individuals for seven VEGF promoter polymorphisms [−417C/T (rs833062), −172C/A (rs59260042), −165C/T (rs79469752), −160C/T, −152G/A (rs13207351), −141A/C (rs28357093) and −116G/A (rs1570360)] by direct sequencing. The frequency of GG, GA, and AA genotype of −152G/A polymorphism was 26.47 vs 38.34 %, 46.08 vs 51.96 %, and 27.45 vs 9.80 %, in patients and controls, respectively. VEGF −152 AA genotype was significantly associated with increased risk for breast cancer (OR = 4.04, 95 %CI, 1.69–9.68, p = 0.001; recessive model OR = 3.48, 95 %CI, 1.59–7.63, p = 0.001). For VEGF −116G/A polymorphism, G and A allele frequencies were 65.2 vs 76.47 % and 34.8 vs 23.53 % in patients and controls, respectively. Individuals having −116AA genotype (OR = 3.40; 95 %CI, 1.24–9.37; p = 0.014) and A allele (OR = 1.73; 95 %CI, 1.12–2.67; p = 0.012) were associated with increased risk for breast cancer. VEGF −165C/T and −141A/C polymorphisms were associated with reduced risk for breast cancer. There was significantly decreased frequency of CT genotype (4.90 vs 18.63 %; p = 0.002) and T allele (2.45 vs 9.31 %; p = 0.003) of −165C/T polymorphism among breast cancer patients as compared to controls. VEGF −141A and C allele frequency were 96.57 vs 91.18 % and 3.43 vs 8.82 % in patients and controls, respectively. Significant reduced risk for breast cancer was observed with AC genotype (OR = 0.34, 95 %CI, 0.14–0.86; p = 0.019) and C allele (OR = 0.37; 95 %CI, 0.15–0.89; p = 0.023) of −141A/C polymorphism. We did not observe association of VEGF −417T/C, −172C/A, −160C/T polymorphisms with breast cancer risk in the studied subjects (p > 0.05). The VEGF −152G/A and −116G/A polymorphisms were found to be significantly associated with increased risk for breast cancer while −165C/T and −141A/C polymorphisms were found to be associated with decreased risk for breast cancer in Punjabi population from North West India.

Glatt CE, DeYoung JA, Delgado S, Service SK, Giacomini KM, Edwards RH, et al. Screening a large reference sample to identify very low frequency sequence variants: comparisons between two genes. Nat Genet. 2001;27(4):435–8.PubMedCrossRef

Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet. 2001;69(1):124–37.PubMedCentralPubMedCrossRef

Taylor JG, Choi EH, Foster CB, Chanock SJ. Using genetic variation to study human disease. Trends Mol Med. 2001;7(11):507–12.PubMedCrossRef

Eaves IA, Merriman TR, Barber RA, Nutland S, Tuomilehto-Wolf E, Tuomilehto J, et al. The genetically isolated populations of Finland and sardinia may not be a panacea for linkage disequilibrium mapping of common disease genes. Nat Genet. 2000;25(3):320–3.PubMedCrossRef

Fullerton SM, Clark AG, Weiss KM, Nickerson DA, Taylor SL, Stengard JH, et al. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet. 2000;67(4):881–900.PubMedCentralPubMedCrossRef

Rieder MJ, Taylor SL, Clark AG, Nickerson DA. Sequence variation in the human angiotensin converting enzyme. Nat Genet. 1999;22(1):59–62.PubMedCrossRef

Taillon-Miller P, Bauer-Sardina I, Saccone NL, Putzel J, Laitinen T, Cao A, et al. Juxtaposed regions of extensive and minimal linkage disequilibrium in human Xq25 and Xq28. Nat Genet. 2000;25(3):324–8.PubMedCrossRef

Templeton AR, Weiss KM, Nickerson DA, Boerwinkle E, Sing CF. Cladistic structure within the human lipoprotein lipase gene and its implications for phenotypic association studies. Genetics. 2000;156(3):1259–75.PubMedCentralPubMed

Pooley KA, Healey CS, Smith PL, Pharoah PD, Thompson D, Tee L, et al. Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach. Cancer Epidemiol Biomarkers Prev. 2006;15(4):675–82.PubMedCrossRef

10.

Zhao Z, Fu YX, Hewett-Emmett D, Boerwinkle E. Investigating single nucleotide polymorphism (SNP) density in the human genome and its implications for molecular evolution. Gene. 2003;312:207–13.PubMedCrossRef

11.

Oshika Y, Nakamura M, Tokunaga T, Ozeki Y, Fukushima Y, Hatanaka H, et al. Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol. 1998;12(3):541–4.PubMed

12.

Yuan A, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer. 2000;89(6):475–83.PubMedCrossRef

13.

Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27.PubMedCrossRef

14.

Belinsky GS, Claffey KP, Nambiar PR, Guda K, Rosenberg DW. Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line. Mol Carcinog. 2005;43(2):65–74.PubMedCrossRef

15.

Roy H, Bhardwaj S, Yla-Herttuala. Biology of vascular endothelial growth factors. FEBS Lett. 2006;580(12):2879–87.PubMedCrossRef

16.

Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795–803.PubMedCrossRef

17.

Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996;93(8):1493–5.PubMedCrossRef

18.

Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O, Levi BZ. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene. 1998;17(2):227–36.PubMedCrossRef

19.

Stein I, Itin A, Einat P, Skaliter R, Grossman Z, Keshet E. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol. 1998;18(6):3112–9.PubMedCentralPubMed

20.

Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006;8(2):R22.PubMedCentralPubMedCrossRef

21.

Pasqualetti G, Danesi R, Del Tacca M, Bocci G. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics. 2007;8(1):49–66.PubMedCrossRef

22.

Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000;37(6):443–8.PubMedCrossRef

23.

Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12(8):1232–5.PubMedCrossRef

24.

Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63(4):812–6.PubMed

25.

Del Bo R, Scarlato M, Ghezzi S, Martinelli Boneschi F, Fenoglio C, Galbiati S, et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol. 2005;57(3):373–80.PubMedCrossRef

26.

Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003;34(4):383–94.PubMedCrossRef

27.

Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 2005;11(10):3647–53.PubMedCrossRef

28.

Sa-Nguanraksa D, Chuangsuwanich T, Pongpruttipan T, Kummalue T, Rojananin S, Ratanawichhitrasin A, et al. Vascular endothelial growth factor 634G/C polymorphism is associated with increased breast cancer risk and aggressiveness. Mol Med Rep. 2013;8(4):1242–50.PubMed

29.

McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002;62(12):3369–72.PubMed

30.

Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun. 2002;3(4):229–32.PubMedCrossRef

31.

Tzanakis N, Gazouli M, Rallis G, Giannopoulos G, Papaconstantinou I, Theodoropoulos G, et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol. 2006;94(7):624–30.PubMedCrossRef

32.

Cacev T, Loncar B, Seiwerth S, Spaventi S, Kapitanovic S. Vascular endothelial growth factor polymorphisms −1154 G/A and −460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer. DNA Cell Biol. 2008;27(10):569–74.PubMedCrossRef

33.

Ungerback J, Elander N, Dimberg J, Soderkvist P. Analysis of VEGF polymorphisms, tumor expression of VEGF mRNA and colorectal cancer susceptibility in a Swedish population. Mol Med Rep. 2009;2(3):435–9.PubMed

34.

Li Y, Wang Y, Kang S, Wang N, Zhou RM, Duan YN, et al. Association of vascular endothelial growth factor gene polymorphisms with susceptibility to epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(5):717–23.PubMedCrossRef

35.

Salajegheh A, Smith RA, Kasem K, Gopalan V, Nassiri MR, William R, et al. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur J Surg Oncol. 2011;37(1):93–9.PubMedCrossRef

36.

Holt RC, Ralph SA, Webb NJ, Watson CJ, Clark AG, Mathieson PW, et al. Steroid-sensitive nephrotic syndrome and vascular endothelial growth factor gene polymorphisms. Eur J Immunogenet. 2003;30(1):1–3.PubMedCrossRef

37.

Churchill AJ, Carter JG, Ramsden C, Turner SJ, Yeung A, Brenchley PE, et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49(8):3611–6.PubMedCrossRef

38.

Del Bo R, Scarlato M, Ghezzi S, Maestroni A, Sjolind L, Forsblom C, et al. VEGF gene variability and type 1 diabetes: evidence for a protective role. Immunogenetics. 2006;58(2–3):107–12.PubMed

39.

Palmirotta R, Ferroni P, Ludovici G, Martini F, Savonarola A, D’Alessandro R, et al. VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension. Clin Biochem. 2010;43(13–14):1090–5.PubMedCrossRef

40.

Schoppmann SF, Horvat R, Birner P. Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (review). Oncol Rep. 2002;9(3):455–60.PubMed

41.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.PubMedCentralPubMedCrossRef

42.

Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol. 2005;23(8):1782–90.PubMedCrossRef

43.

Schneider BP, Sledge Jr GW. Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol. 2007;4(3):181–9.PubMedCrossRef

44.

Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438(7070):932–6.PubMedCrossRef

45.

Adeli K, Ogbonna G. Rapid purification of human DNA from whole blood for potential application in clinical chemistry laboratories. Clin Chem. 1990;36(2):261–4.PubMed

46.

Churchill AJ, Carter JG, Lovell HC, Ramsden C, Turner SJ, Yeung A, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet. 2006;15(19):2955–61.PubMedCrossRef

47.

Akiyama Y. Transcription factor search version 1.3. 1995. Available from: http://www.cbrc.jp/research/db/TFSEARCH.html, accessed on 31/05/2014.

48.

Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–5.PubMedCrossRef

49.

WHO expert consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.

50.

Brogan IJ, Khan N, Isaac K, Hutchinson JA, Hutchinson IV PV. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol. 1999;60(12):1245–9.PubMedCrossRef

51.

Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 2002;13(1):260–4.PubMed

52.

Smith KC, Bateman AC, Fussell HM, Howell WM. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet. 2004;31(4):167–73.PubMedCrossRef

53.

Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 2004;46(3):293–8.PubMedCrossRef

54.

Coulam CB, Jeyendran RS. Vascular endothelial growth factor gene polymorphisms and recurrent pregnancy loss. Am J Reprod Immunol. 2008;59(4):301–5.PubMedCrossRef

55.

Samli H, Demir BC, Ozgoz A, Atalay MA, Uncu G. Vascular endothelial growth factor gene 1154 G/A, 2578 C/A, 460 C/T, 936 C/T polymorphisms and association with recurrent pregnancy losses. Genet Mol Res. 2012;11(4):4739–45.PubMedCrossRef

56.

Aggarwal S, Parveen F, Faridi RM, Phadke S, Borkar M, Agrawal S. Vascular endothelial growth factor gene polymorphisms in North Indian patients with recurrent miscarriages. Reprod Biomed Online. 2011;22(1):59–64.PubMedCrossRef

57.

Magdoud K, Dendana M, Herbepin V, Hizem S, Ben Jazia K, Messaoudi S, et al. Identification of specific vascular endothelial growth factor susceptible and protective haplotypes associated with recurrent spontaneous miscarriages. Hum Reprod. 2012;27(5):1536–41.PubMedCrossRef

58.

Yang JW, Hutchinson IV, Shah T, Fang J, Min DI. Gene polymorphism of vascular endothelial growth factor −1154 G>A is associated with hypertensive nephropathy in a Hispanic population. Mol Biol Rep. 2011;38(4):2417–25.PubMedCrossRef

59.

Prakash S, Prasad N, Sharma RK, Faridi RM, Agrawal S. Vascular endothelial growth factor gene polymorphisms in North Indian patients with end stage renal disease. Cytokine. 2012;58(2):261–6.PubMedCrossRef

60.

Papazoglou D, Galazios G, Papatheodorou K, Liberis V, Papanas N, Maltezos E, et al. Vascular endothelial growth factor gene polymorphisms and idiopathic recurrent pregnancy loss. Fertil Steril. 2005;83(4):959–63.PubMedCrossRef

61.

Goodman C, Jeyendran RS, Coulam CB. Vascular endothelial growth factor gene polymorphism and implantation failure. Reprod Biomed Online. 2008;16(5):720–3.PubMedCrossRef

62.

Kim OJ, Hong SH, Oh SH, Kim TG, Min KT, Oh D, et al. Association between VEGF polymorphisms and homocysteine levels in patients with ischemic stroke and silent brain infarction. Stroke. 2011;42(9):2393–402.PubMedCrossRef

63.

Yuan Q, Zuo X, Jia J. Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer’s disease among Northern Chinese Han. Neurosci Lett. 2009;457(3):133–6.PubMedCrossRef

64.

Zablotna M, Sobjanek M, Nedoszytko B, Lange M, Kozicka D, Glen J, et al. Association of psoriasis with the VEGF gene polymorphism in the northern Polish population. J Eur Acad Dermatol Venereol. 2013;27(3):319–23.PubMedCrossRef

65.

Yang X, Deng Y, Gu H, Lim A, Altankhuyag A, Jia W, et al. Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes. Mol Vis. 2011;17:3088–96.PubMedCentralPubMed

66.

Bluher M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr Opin Lipidol. 2010;21(1):38–43.PubMedCrossRef

67.

Trentham-Dietz A, Newcomb PA, Egan KM, Titus-Ernstoff L, Baron JA, Storer BE, et al. Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control. 2000;11(6):533–42.PubMedCrossRef

68.

Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91.PubMedCrossRef

69.

Carmichael AR, Bates T. Obesity and breast cancer: a review of the literature. Breast. 2004;13(2):85–92.PubMedCrossRef

70.

Mannisto S, Pietinen P, Pyy M, Palmgren J, Eskelinen M, Uusitupa M. Body-size indicators and risk of breast cancer according to menopause and estrogen-receptor status. Int J Cancer. 1996;68(1):8–13.PubMedCrossRef

71.

Huang Z, Willett WC, Colditz GA, Hunter DJ, Manson JE, Rosner B, et al. Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses’ Health Study. Am J Epidemiol. 1999;150(12):1316–24.PubMedCrossRef

72.

Busby S, Ebright RH. Transcription activation by catabolite activator protein (CAP). J Mol Biol. 1999;293(2):199–213.PubMedCrossRef

73.

Lawson CL, Swigon D, Murakami KS, Darst SA, Berman HM, Ebright RH. Catabolite activator protein: DNA binding and transcription activation. Curr Opin Struct Biol. 2004;14(1):10–20.PubMedCentralPubMedCrossRef

74.

Ronco AL, De Stefani E, Deneo-Pellegrini H. Risk factors for premenopausal breast cancer: a case–control study in Uruguay. Asian Pac J Cancer Prev. 2012;13(6):2879–86.PubMedCrossRef

75.

Ronco AL, De Stefani E, Deneo-Pellegrini H, Quarneti A. Diabetes, overweight and risk of postmenopausal breast cancer: a case–control study in Uruguay. Asian Pac J Cancer Prev. 2012;13(1):139–46.PubMedCrossRef

76.

Shamsi U, Khan S, Usman S, Soomro S, Azam I. A multicenter matched case control study of breast cancer risk factors among women in Karachi, Pakistan. Asian Pac J Cancer Prev. 2013;14(1):183–8.PubMedCrossRef

77.

Sun JW, Li XR, Gao HY, Yin JY, Qin Q, Nie SF, et al. Electromagnetic field exposure and male breast cancer risk: a meta-analysis of 18 studies. Asian Pac J Cancer Prev. 2013;14(1):523–8.PubMedCrossRef

78.

Zhang YF, Kang HB, Li BL, Zhang RM. Positive effects of soy isoflavone food on survival of breast cancer patients in China. Asian Pac J Cancer Prev. 2012;13(2):479–82.PubMedCrossRef

79.

Zhou LP, Luan H, Dong XH, Jin GJ, Man DL, Shang H. Association between XRCC5, 6 and 7 gene polymorphisms and the risk of breast cancer: a HuGE review and meta-analysis. Asian Pac J Cancer Prev. 2012;13(8):3637–43.PubMedCrossRef

80.

Zhou P, Huang W, Chu X, Du LF, Li JP, Zhang C. The lymphotoxin-α 252A>G polymorphism and breast cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(5):1949–52.PubMedCrossRef

81.

Colditz GA, Kaphingst KA, Hankinson SE, Rosner B. Family history and risk of breast cancer: nurses’ health study. Breast Cancer Res Treat. 2012;133(3):1097–104.PubMedCentralPubMedCrossRef

82.

Llanos AA, Dumitrescu RG, Marian C, Makambi KH, Spear SL, Kallakury BV, et al. Adipokines in plasma and breast tissues: associations with breast cancer risk factors. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1745–55.PubMedCentralPubMedCrossRef

83.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 31/05/2014.

84.

Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15(6):556–65.PubMedCentralPubMedCrossRef

Titel: Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in Punjabi population from North West India
verfasst von: Ruhi Kapahi
Kamlesh Guleria
Vasudha Sambyal
Mridu Manjari
Meena Sudan
Manjit Singh Uppal
Neeti Rajan Singh
Publikationsdatum: 01.11.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 11/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2404-0

Springer Medizin

Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in Punjabi population from North West India

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2014

Podoplanin expressing cancer-associated fibroblasts in oral cancer

Different mutational characteristics of TSG in cell lines and surgical specimens

Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies

Circulating levels and clinical implications of epithelial membrane antigen and cytokeratin-1 in women with breast cancer: can their ratio improve the results?

EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study

Chronic atrophic gastritis in association with hair mercury level

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie